WHAT IS CLAIMED IS:

- 1. An isolated polynucleotide comprising a member selected from the group consisting of:
- (a) a polynucleotide encoding the polypeptide comprising amino acid 1 to amino acid 142 of SEQ ID NO:2;
- (b) a polynucleotide capable of hybridizing to and which is at least 70% identical to the polynucleotide of (a); and
 - (c) a polynucleotide fragment of the polynucleotide of (a) or (b).
- 2. The polynucleotide of claim 1 encoding the polypeptide comprising amino acid 1 to amino acid 142 as set forth in SEQ ID NO:2.
- 3. The polynucleotide of claim 1 wherein the polynucleotide is DNA.
- 4. The polynucleotide of claim 1 wherein the polynucleotide is RNA.
- 5. The polynucleotide of claim 1 wherein the polynucleotide is genomic DNA.
- 6. The polynucleotide of claim 2 encoding the polypeptide comprising amino acids 1 to 142 of SEQ ID NO:2.
- 7. The polynucleotide of claim 2 comprising the sequence as set forth in SEQ ID NO:1 from nucleotide 1 to nucleotide 600.
- 8. The polynucleotide of claim 2 comprising the sequence as set forth in SEQ ID NO:2 from nucleotide 46 to nucleotide 471.
- 9. An isolated polynucleotide comprising a member selected from the group consisting of:
- (a) a polynucleotide which encodes a polypeptide having the amino acid sequence expressed by the DNA contained in ATCC Deposit No. 75514;
- a polynucleotide capable of hybridizing to and which is at least 70% identical to the polynucleotide of (a); and
 - (c) a polynucleotide fragment of the polynucleotide of (a) or (b).
- 10. The isolated polynucleotide of claim 9 comprising a sequence which encodes a polypeptide having the amino acid sequence expressed by the DNA contained in ATCC Deposit No. 75514.

- 11. A vector containing the DNA of claim 2.
- 12. A host cell genetically engineered with the vector of claim 11.
- 13. A process for producing a polypeptide comprising: expressing from the host cell of claim 12 the polypeptide encoded by said DNA.
- 14. A process for producing cells capable of expressing a polypeptide comprising genetically engineering cells with the vector of claim 11.
- 15. A polypeptide selected from the group consisting of: (i) a polypeptide having the deduced amino acid sequence of SEQ ID NO:2 and fragments, analogs and derivatives thereof and (ii) a polypeptide encoded by the DNA of ATCC Deposit No. 75514 and fragments, analogs and derivatives of said polypeptide.
- 16. The polypeptide of claim 15 wherein the polypeptide has the deduced amino acid sequence of SEQ4D NØ:2.
- 17. An antibody against the polypeptide of claim 15.
- 18. A compound which inhibits the polypeptide of claim 15.
- 19. A compound which activates the polypeptide of claim 15.
- 20. A method for the treatment of a patient having need of HMF comprising: administering to the patient a therapeutically effective amount of the polypeptide of claim 15.
- 21. The method of claim 20, wherein the therapeutically effective amount of the polypeptide is administered to treat leukemia.
- 22. The method of claim 20, wherein the polypeptide is administered by providing to the patient DNA encoding said polypeptide and expressing said polypeptide *in vivo*.
- 23. A method for the treatment of a patient having need to inhibit HMF comprising: administering to the patient a therapeutically effective amount of the compound of claim 18.

- 24. A process for identifying compounds active as agonists or antagonists to HMF comprising:
- combining a compound to be screened, the polypeptide of claim 15 and a reaction mixture containing cells under conditions where the cells are normally stimulated by said polypeptide, said reaction mixture containing a label incorporated into the cells as they proliferate; and
- determining the extent of proliferation of the cells to identify if the compound is an effective agonist or antagonist.
- 25. A process for diagnosing a disease or the susceptibility to a disease related to the underexpression of the polypeptide of claim 15 comprising:

detecting in a sample derived from a host a nutation in the nucleic acid sequence of claim 1.

A diagnostic process comprising: 26. the presence of the polypeptide of claim 15 in a sample derived from a host.

36